Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AbbVie (DE:4AB)
XETRA:4AB
Holding DE:4AB?
Track your performance easily
4AB Stock Chart & Stats
Day’s Range― - ―
52-Week Range€141.98 - €192.50
Previous CloseN/A
Volume1.25K
Average Volume (3M)1.27K
Market Cap
$286.51B
Enterprise Value€413.77B
Total Cash (Recent Filing)$6.42B
Total Debt (Recent Filing)$36.44B
Price to Earnings (P/E)61.3
Beta-0.05
Next Earnings
Jan 31, 2025EPS Estimate
2.84Last Dividend Ex-Date
Jan 15, 2025Dividend Yield3.64%
Share Statistics
EPS (TTM)2.64
Shares Outstanding1,767,140,400
10 Day Avg. Volume988
30 Day Avg. Volume1,270
Standard Deviation0.07
R-Squared0.04
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.42
Price to Cash Flow (P/CF)13.80
P/FCF Ratio13.10
Enterprise Value/Market Cap1.44
Enterprise Value/Revenue7.45
Enterprise Value/Gross Profit12.20
Enterprise Value/Ebitda22.73
Forecast
1Y Price Target
€193.95Price Target Upside14.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
AbbVie News
PremiumThe Fly
AbbVie rises 7.8%
PremiumThe Fly
AbbVie rises 7.4%
Bulls Say, Bears Say
Bulls Say
Aesthetics MarketABBV is a dominant player in the global aesthetics market, with long-term aesthetics revenue guidance of over $9 billion in 2029 remaining unchanged, indicating potential market recovery and new product launches.
Product MomentumMomentum for Skyrizi and Rinvoq remains strong with significant year-over-year growth in the US market, demonstrating robust demand.
Stock ValuationThe current valuation of AbbVie is seen as an increasingly attractive entry point after a recent share pullback.
Bears Say
Earnings And Sales ForecastRevenues and EPS reductions are anticipated due to continued weakness in Aesthetics and delayed pipeline launches, affecting financial projections.
Financial ImpairmentA $3.5 billion impairment charge will be recognized due to the failure of emraclidine, impacting financial statements.
Market Competition And Stock ValuationConcerns about the ability to retain strong formulary positions amid new competitors are potentially capping the stock's price-to-earnings multiple.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.08% Insiders
21.89% Mutual Funds
0.44% Other Institutional Investors
57.04% Public Companies and Individual Investors
4AB FAQ
What was AbbVie’s price range in the past 12 months?
AbbVie lowest stock price was €141.98 and its highest was €192.50 in the past 12 months.
What is AbbVie’s market cap?
AbbVie’s market cap is $286.51B.
When is AbbVie’s upcoming earnings report date?
AbbVie’s upcoming earnings report date is Jan 31, 2025 which is yesterday.
How were AbbVie’s earnings last quarter?
AbbVie released its earnings results on Oct 30, 2024. The company reported €2.877 earnings per share for the quarter, beating the consensus estimate of €2.8 by €0.077.
Is AbbVie overvalued?
According to Wall Street analysts AbbVie’s price is currently Undervalued.
Does AbbVie pay dividends?
AbbVie pays a Quarterly dividend of €5.985 which represents an annual dividend yield of 3.64%. See more information on AbbVie dividends here
What is AbbVie’s EPS estimate?
AbbVie’s EPS estimate is 2.84.
How many shares outstanding does AbbVie have?
AbbVie has 1,767,140,400 shares outstanding.
What happened to AbbVie’s price movement after its last earnings report?
AbbVie reported an EPS of €2.877 in its last earnings report, beating expectations of €2.8. Following the earnings report the stock price went up 4.068%.
Which hedge fund is a major shareholder of AbbVie?
Currently, no hedge funds are holding shares in DE:4AB
---
AbbVie Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€193.95 (14.57% Upside)
€193.95 (14.57% Upside)
Blogger Sentiment
Bullish
DE:4AB Sentiment 94%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $310.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.48%
12-Months-Change
Fundamentals
Return on Equity
56.06%
Trailing 12-Months
Asset Growth
5.29%
Trailing 12-Months
Company Description
AbbVie
AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
---
4AB Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
AbbVie demonstrated strong commercial, operational, and R&D execution with significant growth from its ex-HUMIRA platform, increased revenue and EPS guidance, and successful acquisition and integration of Cerevel Therapeutics. However, challenges remain with declining HUMIRA sales, aesthetic market headwinds, and competitive pressures on IMBRUVICA.Read More>---
4AB Net revenue Breakdown
48.12% Immunology
14.21% Neuroscience
12.59% Other Key Products
10.89% Oncology
14.19% Other
---
4AB Stock 12 Month Forecast
Average Price Target
€193.95
▲(14.57% Upside)
Technical Analysis
Bristol-Myers Squibb
―
Eli Lilly & Co
―
Johnson & Johnson
―
Merck & Company
―
Pfizer
―
Best Analysts Covering 4AB
1 Year
1 Year Success Rate
15/17 ratings generated profit
1 Year Average Return
+13.67%
reiterated a buy rating 10 days ago
Copying Mohit Bansal's trades and holding each position for 1 Year would result in 88.24% of your transactions generating a profit, with an average return of +13.67% per trade.
---